---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Effects of other drugs"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Effects of other drugs. Topics: Medications disallowed and allowed in the phase 3 trials, GLP-1 receptor agonists: exposure to aroxybutynin and atomoxetine (APC-APN-201), Atomoxetine label: strong CYP2D6 inhibitors, Atomoxetine label: monoamine oxidase inhibitors, and 3 further topics. 7 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on AD109

<a id="topic-2.1.2.9.1-1"></a>

### Medications disallowed and allowed in the phase 3 trials

> “Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

| Medication status in the phase 3 trials | Medications |
| --- | --- |
| Disallowed | “MAOIs, NRIs, and TCAs” |
| Disallowed | “Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors” |
| Disallowed | “Muscle relaxants (in people ages >65 years), pressor agents, central agonist antihypertensives, and amphetamines” |
| Disallowed | “Oral anticholinergics, and cholinesterase inhibitors” |
| Disallowed | “Modafinil, armodafinil, solriamfetol, and pitolisant” |
| Allowed | “Antihypertensives (except central agonist)” |
| Allowed | “Inhaled corticosteroid, and antidiabetics, including those associated with weight loss” |

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.9.1-2"></a>

### GLP-1 receptor agonists: exposure to aroxybutynin and atomoxetine (APC-APN-201)

> “This was an open-label, parallel-arm, 6-week phase 2 study of AD109 in participants with mild-to-severe OSA and obesity, administered either alone or while remaining on a stable maintenance dose of a GLP-1 RA (tirzepatide, semaglutide, or liraglutide).”
> “Geometric mean ratios (GMR; AD109+GLP-1 RA/AD109 alone [90% CI]) of aroxybutynin for Cmax, AUClast, and AUCinf were 100.6 (68.0–148.8), 142.0 (102.1–197.5), and 152.7 (111.0–210.1), respectively. GMR of atomoxetine for Cmax, AUClast, and AUCinf were 67.0 (51.0–88.1), 81.9 (57.0–117.7), and 78.2 (51.3–119.1), respectively.”
> “AD109 was generally safe and well-tolerated in both treatment arms of this phase 2 trial, without large differences in PK when co-administered with GLP-1 RA.”

Source: [Yao et al. (2026)](https://academic.oup.com/sleep/article/49/Supplement_1/A299/8673293)

<a id="topic-2.1.2.9.1-3"></a>

### Atomoxetine label: strong CYP2D6 inhibitors

> “With concomitant use of STRATTERA and a strong CYP2D6 inhibitor, increase the titration interval”
> “Concomitant use of STRATTERA (20 mg BID for 5 days) with paroxetine (20 mg QD for 17 days), a known inhibitor of CYP2D6, in subjects who were not CYP2D6 poor metabolizers resulted in a 6.5-fold higher plasma exposure (AUC) to atomoxetine at steady state.”
> “After concomitant use of STRATTERA with paroxetine or fluoxetine, the Css, max of atomoxetine was about 3-to 4-fold greater than the use of STRATTERA alone”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.1-4"></a>

### Atomoxetine label: monoamine oxidase inhibitors

> “STRATTERA is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue, or in patients who stopped an MAOI within 14 days.”
> “As with other drugs affecting brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability with fluctuations of vital signs, extreme agitation progressing to delirium/coma) with concomitant use of STRATTERA and an MAOI.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.1-5"></a>

### Atomoxetine label: drugs that affect gastric pH and drugs highly bound to plasma protein

> “Drugs that elevate gastric pH had no effect on atomoxetine bioavailability.”
> “Similarly, warfarin, acetylsalicylic acid, phenytoin, or diazepam did not affect the binding of atomoxetine to human albumin.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.1-6"></a>

### Oxybutynin label: CYP3A4 inhibitors

> “Mean oxybutynin plasma concentrations were approximately 2 fold higher when DITROPAN XL® was administered with ketoconazole, a potent CYP3A4 inhibitor. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are co-administered.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.9.1-7"></a>

### Oxybutynin label: other anticholinergic drugs

> “The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
